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Abstract: Psoriasis is a chronic, immune mediated inﬂ  ammatory disease characterized by 
increased cell signalling via cytokines and chemokines on a background of up-regulated gene 
expression. There is substantial evidence that psoriasis should be regarded as more than a 
cutaneous disease; major psychological morbidity and increased mortality from cardiovascular 
disease and cancer are increasingly recognized. Improved understanding of the genetic and immu-
nological mechanisms underpinning psoriasis has occurred concurrently with the development 
of targeted biological therapies including inﬂ  iximab. These newer therapeutic approaches can 
be very effective but their long term safety proﬁ  le is not yet fully determined.
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Introduction and clinical features
Psoriasis, a chronic inﬂ  ammatory disease, affects 1.5% to 2.5% of the UK population 
and is diagnosed on clinical grounds (Gelﬂ  and et al 2005). A relapsing and remitting 
course is characteristic. There are several different phenotypes which frequently overlap 
and switching between phenotypic groups may occur. Around 80% of individuals 
present with chronic plaque psoriasis characterized by well demarcated, red, thickened 
patches of skin which become elevated and covered with an adherent, silvery scale 
(Lebwohl and Callen 2003). Typically plaques are located on the extensor aspect of 
knees, elbows, hairline, scalp, intergluteal cleft and lumbosacral area. Nail involvement, 
which occurs in 30% to 50% of patients, is characterized by pitting of the nail surface, 
onycholysis (separation of nail plate from the nail bed) and subungal hyperkeratosis 
(Scher 1985). Guttate psoriasis is typiﬁ  ed by the acute onset of multiple small patches 
predominantly located on the trunk. This form may be the initial presentation in 
children with a family history of psoriasis. In up to 80% of cases there is a history 
of a preceding sore throat (Telfer et al 1992). Erythrodermic psoriasis denotes the 
involvement of the entire skin surface which, although rare, is signiﬁ  cant because it 
can be life threatening with a risk of sepsis and thermoregulatory disruption. Pustular 
psoriasis may be localized or generalized. In the generalized variant sheets of sterile 
pustules are found on a background of red skin. Fever, arthralgia and malaise are 
common accompaniments. In palmoplantar pustulosis clusters of sterile pustules stud 
the thenar and hypothenar eminences as well as the plantar surface, especially the 
instep. Controversy exists as to whether or not these pustular eruptions are part of the 
psoriasis spectrum or are separate entities. Psoriatic arthritis affects between 5% and 
30% of psoriasis patients and can be aggressive and deforming. Both the axial and 
the peripheral joints may be involved with several overlapping patterns: asymmetric, 
oligoarticular disease, predominant distal arthritis characterized by involvement of 
the distal interphalangeal joints, arthritis mutilans, symmetric polyarthritis (closely 
resembling rheumatoid arthritis) and axial involvement/spondolarthropathy (Espinoza 
et al 1992; Moll et al 1973). Enthesopathy and dactylitis are characteristic features.
Symptoms of psoriasis commonly include itching and tightness of the skin as well 
as fatigue (Burd 2006). At diagnosis, patients are educated as to the likely requirement Therapeutics and Clinical Risk Management 2008:4(6) 1166
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for life-long treatment. Spontaneous remission is reported 
but relapses are common. The importance of recognizing 
common co morbidities such as cardiovascular disease and 
metabolic syndrome is increasingly being recognized.
Comorbidities and risk factors
As is the case with other chronic inﬂ  ammatory diseases, 
psoriasis is associated with increased cardiovascular 
morbidity. In patients with severe psoriasis, the overall 
cardiovascular mortality risk for patients admitted to hospital 
at least once for their skin, is increased by 50% (SMR 1.52; 
95% CI; 1.44–1.60) (Mallbris et al 2004). Psoriasis was 
demonstrated to be an independent risk factor for myocardial 
infarction in a population based cohort study. The risk is 
greatest for younger patients with severe disease even when 
corrected for traditional vascular risk factors (Gelfand et al 
2006).
The increased cardiovascular morbidity and mortality 
in patients with psoriasis is likely due to several inter-
related factors including: smoking, alcohol consumption, 
dyslipidemia, obesity, chronic inﬂ  ammation. The risk of 
psoriasis is higher in smokers and former smokers than in 
those who have never smoked (Lebowohl and Callen 2006). 
Alcohol consumption is increased in patients with psoriasis 
(Poikolainen et al 1999). Increased rates of hyperlipidemia 
occur in those with severe, long standing psoriasis (Uyanik 
et al 2002). The prevalence of obesity is twice that of the 
normal population (Lebowohl and Callen 2006). A recent 
study identiﬁ  ed increased adiposity and weight gain as risk 
factors for incident psoriasis (Setty et al 2007).
As well as physical morbidity, the psychological and 
psychosocial effects of psoriasis are increasingly being 
recognized. The impact on quality of life equates to, and 
sometimes exceeds, that found in hypertension, heart disease, 
diabetes and cancer (Rapp et al 1999).
Assessing disease severity
When categorizing psoriasis as mild, moderate or severe, 
physicians may consider several parameters including: 
response to treatment, impact on quality of life (Dermatology 
Life Quality Index; DLQI), body surface area involved 
(Physician Global Assessment; PGA), disease activity 
(plaque redness, scale and thickness – psoriasis area and 
severity index).
Psoriasis Area and Severity Index (PASI) is considered 
by many to be the gold standard severity assessment tool 
and consists an average measure of 4 parameters; redness, 
thickness and scaliness of lesions and extent of disease. 
Each parameter is graded as 0–4 with 0 equating to no 
disease and 4 severe involvement. The body is divided into 
4 areas (head, arms, trunk to groin, legs to top of buttocks). 
The scores are summed, a percentage of the area covered 
by psoriasis estimated and a multiplier applied to each area 
generating a ﬁ  nal PASI. PASI ranges from 0 to 72 with 
PASI   10 recognized as indicative of severe disease 
(Feldman and Krueger 2005; Finlay 2005). A 75% reduction 
in PASI from baseline (PASI 75) is commonly used as an 
indicator of disease response, and in most clinical trials this 
is the primary efﬁ  cacy endpoint. For individual patients a 
smaller improvement in PASI can be clinically meaningful 
(Carlin et al 2004). This is reﬂ  ected in clinical trials which 
frequently report PASI 50 rates as well as PASI 75.
In day to day practice, a PGA is commonly used. A static 
form records disease at a solitary time point. In contrast, the 
dynamic form assesses global improvement compared to 
baseline (Feldman et al 2005). A static PGA score ranges 
from 0 (no psoriasis) to 7 (severe disease).
Quality of life is most frequently assessed using a skin-
speciﬁ  c 10 point questionnaire, the DLQI. This assesses the 
impact of disease over 6 domains each on a scale of 0 (not 
at all) to 3 (very much). A score of 0 indicates that psoriasis 
or its treatment is not impacting on health related quality 
of life at all. In contrast, a score  10 indicates a very large 
effect on life quality (Lewis et al 2004; Findlay 2005a). 
A change of 5 points is considered to be clinically relevant 
(Mease et al 2006).
Economic impact of psoriasis
Patients with severe disease represent around 20% to 30% of 
all psoriasis patients. Systemic therapies are frequently 
required and the economic burden for patients and health 
service alike is considerable. United Kingdom estimates 
of cost of treatment for moderate to severe disease vary 
from £45.5 to £80 million (Van de Kerkhof 2003) Costs 
for individual patients are considerable and may include 
difficulties with employment (NICE 2006; Scottish 
Medicines Consortium 2007).
Epidemiology and genetics
A quarter of patients develop the disease before the age of 
20 years. A further peak in incidence is recorded in the ﬁ  fth 
and sixth decades (Lebwohl 2003; Burd 2006). The age of 
onset seems to be genetically determined. Men and women are 
equally frequently affected. Caucasians are more commonly 
affected than other ethnic groups (Lebwohl 2003). Environ-
mental factors may trigger or exacerbate existing disease. Therapeutics and Clinical Risk Management 2008:4(6) 1167
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Streptococcal antigens have been the focus of much research. 
The streptococcal M protein is homologous to the 50 kDa 
type I keratin, K14 and a 67 kDa streptococcal protein is 
homologous to myosin and the beta chain of the class II 
HLA antigens. These observations suggest that molecular 
mimicry between streptococcal protein and keratin may, in 
some individuals, lead to activation of autoreactive T cells 
(Valdimarsson et al 1997; Gudmundsdottir et al 1999; Camp 
et al 2006).
Familial clustering and high concordance rates in 
monozygotic twins indicate that psoriasis is highly heritable 
(Lomholt 1963). Linkage analysis has revealed multiple 
susceptibility loci with evidence for a major risk gene on 
chromosome 6p (PSORS 1) highly associated with HLA-Cw6 
(Elder 2006). Interestingly, several other suspected loci are 
shared with other inﬂ  ammatory and autoimmune conditions 
such as inﬂ  ammatory bowel disease and atopic dermatitis 
(Cookson et al 2001). A large number of possible susceptibility 
polymorphisms are being described in large scale whole 
genome association scans, including polymorphisms in the 
IL-23 receptor and its ligand (Capon et al 2007).
Pathogenesis
Microscopically, psoriasis is characterized by a thickened 
epidermis with the retention of nucleated keratinocytes in 
the stratum corneum, loss of keratinocyte differentiation, an 
inﬂ  ammatory cell inﬁ  ltrate, mainly neutrophils and lympho-
cytes and vascular proliferation. T cells have been shown to 
play a pivotal role in pathogenesis driving epidermal hyper-
plasia. Multiple studies have demonstrated the importance of 
speciﬁ  c T cell subsets and dendritic antigen presenting cells 
(Gilhar et al 1997; Krueger et al 2002). The cytokine network 
model proposes activation of immunocytes by, for example, 
infections, medications and trauma, triggering a cascade of 
cytokines, chemokines and growth factors (Nickoloff 1999). 
Tumor necrosis factor alpha (TNF alpha) produced by antigen 
presenting cells, T cells and keratinocytes, is known to be 
elevated in psoriatic plaques, and serum levels correlate with 
disease activity. New biological interventions have targeted 
T cells, antigen presenting cells and TNF alpha.
Therapeutic options for psoriasis
For most patients, topical therapies supervised by their 
primary care physicians, sufﬁ  ce. Topical corticosteroids, 
vitamin D analogs, coal tar and tazoretene are commonly 
prescribed (Bundu-Kamara 2002; Clements et al 2006; Smith 
et al 2006) For those with moderate –severe disease, usually 
def ined as disease affecting  5% to 10% of body surface 
area (BSA), topical treatment can be labor intensive and 
messy to apply. Systemic therapies and phototherapies are, 
for this group, often more practical and efﬁ  cacious (Cather 
et al 2005).
In addition, more limited psoriasis affecting only the 
face, hands or feet, may merit systemic intervention because 
of cosmetic or functional difﬁ  culty. Phototherapy using 
either narrow band ultraviolet B or photochemotherapy 
using long wave ultraviolet A is appropriate for those with 
an inadequate response to topical treatments or for those 
with extensive disease (Bandu-Kamara 2002). Treatment is 
usually delivered 2 to 3 times a week in dedicated centers 
staffed by appropriately trained individuals. Skin burning, 
photoaging and skin cancer may be limiting factors. For those 
who fail to respond or those in whom relapse after treatment 
is rapid, systemic therapies such as methotrexate, acitretin, 
ciclosporin and fumaric acid esters, may be employed 
(Lebwohl 2003). These are prescribed by hospital specialists 
and require close supervision and monitoring. All patients 
are fully counselled regarding potential adverse effects and 
toxicity. Regular monitoring is essential. Even with the use 
of systemic therapies, additional topical applications are 
frequently used during disease exacerbations or at therapy 
resistant sites.
Place of inﬂ  iximab in treatment 
of psoriasis
Currently available biological treatments in Europe 
comprise 3 TNF alpha antagonists (inﬂ  iximab, adalimumab 
and etanercept) and the T cell targeted treatment, efalizumab. 
The licensed indication for each of these is similar: moderate 
to severe plaque psoriasis in patients who have failed to 
respond to, have a contraindication to or are intolerant of other 
systemic therapies including ciclosporin, methotrexate and 
psoralen and ultraviolet A light (PUVA). In the US, a second 
T cell targeted treatment (alefacept) is also available. The 
licensed indication for biological treatment is also different 
in the US, with no requirement for patients to have failed, 
or be intolerant of other systemic agents. Ustekimumab, 
a monoclonal antibody directed against IL-12 and IL-23, has 
completed phase 3 trials and is awaiting marketing authoriza-
tion from the licensing agencies in Europe and the US.
Inﬂ  iximab
Inﬂ  iximab (Remicade®) is a chimeric (75% human, 25% 
murine) IgG1 monoclonal antibody which targets TNF alpha. 
Infliximab binds with high affinity to both soluble and 
membrane-bound TNF alpha and inhibits the ability of Therapeutics and Clinical Risk Management 2008:4(6) 1168
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TNF alpha to bind to the TNF receptor. Inﬂ  iximab is licensed 
for use in rheumatoid arthritis, Crohn’s disease, anklyosing 
spondylitis and psoriatic arthritis. For patients with psoriasis, 
inﬂ  iximab is infused at a dose of 5 mg/kg at week 0, 2 and 6 and 
then at 8- to 12-weekly intervals thereafter. There are data 
on efﬁ  cacy in psoriasis from psoriatic arthritis trials and 
also from trials primarily designed to investigate efﬁ  cacy in 
plaque psoriasis.
A double-blind, placebo-controlled phase 2 trial (SPIRIT) 
randomized 249 patients in a 2:2:1 ratio to receive inﬂ  iximab 
3 mg/kg, 5 mg/kg or placebo administered at weeks 0, 2 and 6. 
Randomized patients had plaque psoriasis of at least 6 months 
duration, and PASI   12 and plaques covering  10% BSA. 
The median baseline PASI was 20, 20 and 18, median BSA 
29%, 25% and 26% for 3 mg/kg, 5 mg/kg and placebo groups, 
respectively. All patients had systemic therapies or light 
therapy discontinued 1 month before and during the trial. The 
primary endpoint was the proportion of patients achieving a 
PASI 75 at week 10. At week 26 patients with a PGA   3 
were eligible for a single further infusion. Patients were fol-
lowed up to week 26 to assess duration of response. At week 
10, 72% of the 3 mg/kg and 88% of the 5 mg/kg group had 
achieved a PASI 75. In contrast, only 6% of placebo group 
achieved the primary endpoint (p   0.001). PGA results cor-
roborated PASI results with 72% and 90% of patients in the 
inﬂ  iximab 3 and 5 mg/kg groups respectively achieving PGAs 
of minimal or cleared psoriasis at week 10. Median baseline 
DLQI scores were 11, 12 and 14 for 3 mg/kg, 5 mg/kg and 
placebo respectively. The median changes in DLQI from 
baseline to week 10 were –8 and –10 for the 3 and 5 mg/kg 
groups respectively compared to no change in the placebo 
group (p   0.001) (Gottlieb et al 2004).
In a phase 3, multi-center, double-blind placebo con-
trolled trial at 32 centers in Europe and Canada (EXPRESS), 
378 patients with plaque psoriasis were randomized in a 4:1 
ratio to inﬂ  iximab 5 mg/kg or placebo administered at week 
0, 2, 6 and then at 8 weekly intervals to week 46 (Reich et al 
2005). At week 24 placebo-treated patients crossed over to 
inﬂ  iximab. Those eligible for inclusion had moderate to 
severe plaque psoriasis with PASI   12 and a BSA   10% 
affected where PUVA or systemic therapies would have 
been appropriate. Systemic and photo therapies were stopped 
1 month before entry and during the trial. The groups were 
comparable in terms of baseline PASI, body surface area 
involvement and nail severity index. The primary endpoint 
was the proportion of patients achieving a PASI 75 after 
10 weeks. The secondary endpoints included the PASI 50 
and PASI 90 at week 10. Intention to treat analysis was used 
for primary endpoints and non ITT analysis for secondary 
endpoints such as PASI 50, 75 and 90 at week 24 and 50. 
After 10 weeks 80% of patients achieved a PASI 75 and 
57% a PASI 90 compared to 3% and 1% in the placebo 
group respectively (p   0.0001). Response was maintained 
at week 24 with a PASI 75 of 82% and PASI 90 of 58% in 
inﬂ  iximab group. By week 50 the proportion achieving a 
PASI 75 and PASI 90 had fallen to 61% and 45% respec-
tively. 83% of patients achieved a PGA of clear or minimal 
at week 10 (p   0.0001) but by week 50 this had fallen to 
53%. A response to treatment was seen as early as week 2. By 
week 6, signiﬁ  cantly more inﬂ  iximab patients had achieved 
a PASI 75 and PASI 90 (p   0.0001). The loss of clinical 
response correlated with low inﬂ  iximab serum concentra-
tions which was partly attributed to the development of 
anti-inﬂ  iximab antibodies.
The suggestion that for some patients more regular 
infusions are required was investigated in a further study 
(EXPRESS II) which compared regular versus on-demand 
maintenance regimens (Menter et al 2007). In this 
randomized, double-blind placebo-controlled trial eligible 
patients were randomly assigned to placebo or inﬂ  iximab 
in a 2:3 ratio. Induction doses of inﬂ  iximab were either 
3 or 5 mg/kg given at week 0, 2 and 6. At week 14, patients 
in the inﬂ  iximab group were randomized again to either 
8 weeks continuous maintenance therapy or as required 
therapy at the same dose administered in the induction 
phase. As required inﬂ  iximab was given when the PASI 
improvement from baseline was less than 75% at the 
4-weekly study visits. Patients in the placebo group were 
crossed over at week 16 to receive inﬂ  iximab 5 mg/kg at 
week 16, 18 and 22 and every 8 weeks to week 46. All 
those enrolled had moderate to severe psoriasis (eligible 
for treatment with systemic therapies or phototherapy) with 
a PASI   12 and plaques covering at least 10% BSA. At 
week 10, 75.5% of the 5 mg/kg inﬂ  iximab group and 70.3% 
of the 3 mg/kg group compared to 1.9% of the placebo 
group had achieved a PASI 75. PASI 90 (considered almost 
clear) was achieved by 45.2% of those treated with 5 mg/kg 
inﬂ  iximab and 37.1% of 3 mg/kg inﬂ  iximab compared to 
0.5% of controls, p   0.001. PASI responses were better 
maintained with continuous compared with intermittent 
therapy within each dose and with 5 mg/kg compared with 
3 mg/kg. PGA responders, at week 10, were 76% in the 
5 mg/kg inﬂ  iximab group, 69.8% in 3 mg/kg group and 
1% in the placebo arm. PGA responders were classiﬁ  ed as 
100% clear (clear) or 75% to 99% clear (excellent clearing) 
relative to baseline.Therapeutics and Clinical Risk Management 2008:4(6) 1169
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Patients receiving inﬂ  iximab had more frequent serious 
adverse events than placebo in all studies 6.1% vs 0% 
in SPIRIT, 6% (this included one fatal infection in the 
inﬂ  iximab arm) vs 3% EXPRESS and 2.9% in 5 mg/kg 
group and 1% in 3 mg/kg group versus 2.4% placebo in 
EXPRESS II. Laboratory abnormalities were uncommon, 
the most frequently observed being an elevation in liver 
enzymes. Infusion reactions occurred in 20% in SPIRIT 
compared to 2% placebo. It is not possible to ascertain 
the number of infusion reactions in EXPRESS as data are 
presented as percentage of total number of infusions. Infusion 
reactions were more common when the drug was given on 
an as required basis rather than as planned regular infu-
sions. Twenty-three percent of patients in SPIRIT at week 
26 and 22% at week 46 in EXPRESS developed antibodies. 
There were 2 cases of tuberculosis in the inﬂ  iximab group 
in EXPRESS II. There is some concern that inﬂ  iximab, in 
common with other biological therapies, may increase the 
risk of malignancies. Three patients in EXPRESS had skin 
cancers. The follow-up period in these trials is short and the 
long term safety data are not currently available nor can they 
be extrapolated from other specialities that may have longer 
experience in the use of this drug.
Quality of life
Trials consistently demonstrate an improvement in quality 
of life comparing baseline with week 10 assessments with 
inﬂ  iximab compared to placebo (Gottlieb et al 2004; Reich 
et al 2005; Menter et al 2007). At week 50, however, the 
improvements in quality of life were smaller than at week 10 
in two studies (Reich et al 2005; Menter et al 2007). Speciﬁ  c 
analysis of health related quality of life was undertaken by 
Feldmann et al as part of the SPIRT trial. Inﬂ  iximab 3 mg/kg 
and 5 mg/kg groups showed a median percentage improve-
ment in DLQI scores of 84% and 91% respectively compared 
to 0% in the placebo group (p   0.001). The median decrease 
from baseline DLQI score at week 10 was 8 and 10 for the 
3 and 5 mg/kg groups respectively compared to 0 for placebo 
(p   0.001). Forty percent of the 5 mg/kg patients had a DLQI 
of 0 at week 10 compared to 33% in 3 mg/kg group and 2% 
in placebo group. There was a strong correlation between 
the percentage change in DLQI from baseline to week 10 
and the PASI scores (Feldman et al 2005).
Inﬂ  iximab for psoriatic arthritis
There have been two randomized controlled trials of inﬂ  ix-
imab in psoriatic arthritis. The outcome measures commonly 
used are the American College of Rheumatology (ACR) 
response criteria, the Psoriatic Arthritis Response Criteria 
(PsARC) and health assessment questionnaire (HAQ).
The ACR is a composite score which compares at baseline, 
and then at deﬁ  ned time points thereafter, the tender and 
swollen joint score and 3 out of 5 other measures: patient 
global assessment, physician global assessment, patient pain, 
heath assessment questionnaire and acute phase reactant 
(erythrocyte sedimentation rate or C reactive protein). An ACR 
20 response would be constituted by a 20% improvement in 
tender and swollen joint count and a 20% improvement of 
at least 3 of the 5 other elements in the composite criteria. 
ACR 50 and 70 represent, respectively, at least a 50% and 
70% improvement. Other studies have used PsARC which 
requires at least 30% improvement of tender or swollen joint 
count as well as a 1 point improvement on a 5-point scale in 
patient and or physician global assessment and no worsening 
of any score. Some investigators use a measure of physical 
function, the Health assessment Questionnaire (HAQ), which, 
in studies of rheumatoid arthritis, has been shown to be highly 
discriminative and to correlate well with response to therapy 
(Mease et al 2005).
In a randomized, double-blind, placebo-controlled trial in 
104 patients with psoriatic arthritis (IMPACT) at 16 weeks 
65% of patients treated with inﬂ  iximab achieved an ACR 
20 compared with 10% in the placebo arm. (RR 6.80, 
95% CI 2.89 to 16.01). Forty-six percent of the inﬂ  iximab-
treated patients achieved an ACR 50 (RR 49.00, 95% 
CI 3.06–785.06) and 29% achieved an ACR 70 (RR 31.00 
95% CI 1.90–504.86) compared with none in the placebo 
group. Seventy-ﬁ  ve percent of inﬂ  iximab-treated patients 
achieved a PsARC (RR 3.55, 95% CI 2.05–6.13). Functional 
improvement was demonstrated by improvement in HAQ 
scores with inﬂ  iximab compared to placebo – mean differ-
ence 51.4 (95% CI 48.8–54.72). Radiographic assessments 
were not performed so the potential of inﬂ  iximab to delay 
progression of joint disease could not be commented upon 
(Antoni et al 2005a).
In the phase 3, double-blind, placebo-controlled trial 
(IMPACT II) 200 patients with active psoriatic arthritis were 
treated with inﬂ  iximab 5 mg/kg or placebo at weeks 0, 2, 6 and 
every 8 weeks thereafter up to 1 year (Kavanaugh et al 2007). 
Concomitant methotrexate was permitted but was not manda-
tory. Those randomized to placebo crossed over to inﬂ  iximab 
at week 24. Dose escalation to 10 mg/kg at week 38, was 
permitted in those who had no response or had lost response. 
ACR 20, ACR 50 and ACR 70 responses were maintained with 
continued inﬂ  iximab treatment in the randomized inﬂ  iximab 
group and were substantial following crossover to inﬂ  iximab Therapeutics and Clinical Risk Management 2008:4(6) 1170
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in the placebo/inﬂ  iximab group. For example, ACR 20 was 
achieved by 58.9% and 61.4% of patients in the random-
ized inﬂ  iximab and placebo/inﬂ  iximab groups, respectively. 
At week 54, the ACR response was consistent whether or 
not methotrexate had been used. For example, ACR 20 was 
achieved by 56.8% of patients on inﬂ  iximab plus methotrexate 
and 60.9% of patients on inﬂ  iximab alone. Other efﬁ  cacy 
results such as PsARC and duration of morning stiffness were 
also maintained through to week 54.
Inﬂ  iximab in nail psoriasis
Efﬁ  cacy of inﬂ  iximab in nail psoriasis has been documented 
in case reports, case series and as part of large clinical trials 
of inﬂ  iximab in plaque psoriasis. In a phase 3 study of 
378 patients with moderate to severe psoriasis, 81.8% had 
nail psoriasis at baseline. Inﬂ  iximab 5mg/kg was given at 
week 0, 2 and 6 then 8 weekly to week 46. The Nail Psoriasis 
Severity Index (NAPSI) at baseline was 4.6 in treatment 
group and 4.3 in the placebo group. At week 10 and 24 the 
mean NAPSI scores had improved by 26.8% and 57.2% 
respectively and –7.7% and –4.1% in the placebo group (both 
p   0.001). Psoriasis in the target nail had completely cleared 
in 6.9% in patients at week 10 and 44.7% at week 50 versus 
5.1% in placebo group (p   0.001) (Rich et al 2008).
A small study of 25 patients treated with inﬂ  iximab 
5 mg/kg at week 0, 2, 6, 14 and 22 resulted in a NAPSI 75 
(clinical remission) in all patients by week 22. Remission 
was maintained at follow up 12 weeks after the ﬁ  nal infusion 
(Bianchi et al 2005).
In a small, non-randomized, open-label study of 
18 patients mean NAPSI declined from 55.8 at baseline to 
29.8 at week 14. At week 38, after 6 infusions, there was 
almost complete resolution of nail involvement and improved 
quality of life (Rigopoulos et al 2008).
Inﬂ  iximab in special situations: 
psoriasis in children, erythrodermic 
and pustular psoriasis
At present, there are no clinical trials of infliximab in 
childhood psoriasis. Case reports suggest efficacy in 
psoriasis, including pustular disease and psoriatic arthropathy 
(Menter et al 2004; Pereira et al 2006; Rott et al 2007).
One small series, which incorporates details of previous 
case reports, suggests that inﬂ  iximab is a useful treatment 
in erythrodermic psoriasis (Takahashi et al 2007). The 
patients described frequently had life threatening disease 
highly resistant to multiple previous therapies. Response to 
inﬂ  iximab, which may be combined with systemic therapies 
such as methotrexate or acitretin, is often prompt but long 
term follow-up data are scant.
There are several case reports and case series indicating 
efﬁ  cacy of inﬂ  iximab (used off label) in pustular psoriasis 
(Trent et al 2004; Schmick et al 2004; Lewis et al 2006; 
Weisenseel et al 2006; Vieira et al 2008). Infliximab is 
usually administered every 6 weeks at a dose of 5 mg/kg 
sometimes with the addition of weekly, low dose methotrexate 
(Routhouska et al 2008). At a molecular level, inﬂ  iximab has 
been shown to down regulate disease-promoting chemokines 
such as interleukin 8, GRO-alpha and MCP-1 in pustular 
psoriasis (Benoit et al 2004). Most reports include only small 
numbers of patients with limited follow-up data.
Paradoxically, treatment with inﬂ  iximab has been impli-
cated in the development of pustular psoriasis (Martínez-Morán 
et al 2007) and palmoplantar pustulosis (Mossner et al 2008). 
In the latter report, 5 patients with chronic plaque psoriasis 
developed palmoplantar pustulosis during or after discontinu-
ation of inﬂ  iximab. A review of TNF alpha-induced psoriasis 
or psoriasiform eruptions was published in 2008. Sixty-three 
of the 120 affected patients had been treated with inﬂ  iximab. 
Psoriasis, palmoplantar pustulosis and nail psoriasis had been 
induced immediately after one infusion through to 63 months 
post treatment. The underlying mechanism of induction of 
psoriasis/psoriasiform exanthema in these patients remains 
elusive (Wollina et al 2008). Patients who have developed 
psoriasis or a psoriasiform eruption during treatment with 
one TNF blocker may respond, without adverse event, to an 
alternative TNF antagonist (Collamer et al 2008).
Inﬂ  iximab and pregnancy
TNF antagonists are listed as pregnancy category B drugs: 
animal studies have failed to demonstrate a risk to the fetus but 
there are no adequate and well controlled studies of the effect 
of the drugs on pregnant women. In a series of 32 women, 
identified from the British Society for Rheumatology 
Biologics Register, who were exposed to anti TNF drugs at 
the time of conception, or in the preceding 10 months, 91% 
elected to continue their pregnancies. Seventy-six percent 
delivered health babies and 24% had ﬁ  rst trimester miscar-
riages, a rate consistent with that expected in the general 
population (Hyrich et al 2006).
Safety of and adverse events 
associated with inﬂ  iximab
Inﬂ  iximab is generally well tolerated. Regular infusions 
in a hospital setting provide an opportunity to monitor for 
potential adverse events.Therapeutics and Clinical Risk Management 2008:4(6) 1171
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Most safety data come from the rheumatoid arthritis and 
Crohn’s populations. Inﬂ  iximab has been used extensively in 
the UK by rheumatologists who had the foresight to establish 
a biologics registry under the auspices of the British Society 
of Rheumatology. It is estimated that around 80% of patients 
commencing biological therapies are entered on the register, 
enabling comprehensive data collection on adverse events.
Absolute contraindications to commencement include 
active infections, recurrent or chronic infections, previous 
untreated tuberculosis (TB), moderate to severe cardiac 
failure and recent history of malignancy (except for skin 
cancer such as basal cell carcinoma). In clinical trials upper 
respiratory tract infection, sinusitis, nausea and headache 
are the most commonly reported adverse events (Scheinﬁ  eld 
2004; Hochberg et al 2005).
Infections (including TB)
The most important adverse event of infliximab is the 
increased risk of infection including sepsis and opportunistic 
infection. Patients with predisposing underlying conditions 
such as diabetes mellitus are at higher risk of infection. If any 
severe infection develops inﬂ  iximab should be temporarily 
withdrawn and the need for antibiotics considered.
A recent report from the British Society of Rheumatology 
Biologics Register found that the overall risk of serious infec-
tions in rheumatoid arthritis patients was not increased by anti-
TNF alpha therapy compared to those on standard DMARD 
therapy. There were, however, more opportunistic infections, 
such as histoplasmosis, and more skin and soft tissue infections 
in the cohort on biologic therapy (Dixon et al 2007).
All TNF blockers carry a warning about reactivation of TB 
(black box for inﬂ  iximab) (Centocor®, Remicade® data sheet). 
The boxed warning advises prescribing physicians to screen 
all patients for TB before initiation of therapy, to pretreat 
those with latent disease and to monitor patients for signs and 
symptoms of TB throughout the treatment course with inﬂ  ix-
imab. In a recent review of 130 cases of inﬂ  iximab-associated 
tuberculosis reported to the FDA, many cases occurred in 
patients with a negative tuberculin skin test but with risk 
factors for TB. A fatal outcome was reported in 19 individuals 
(Raval et al 2007). Most cases occur shortly after initiation of 
treatment. Presentation may be with disseminated or military 
tuberculosis. A screening chest x ray is essential and testing 
for tuberculid sensitivity should be considered.
Infusion reactions
Another commonly reported event, occurring in around 
20% of patients, is an infusion reaction especially during 
the ﬁ  rst few infusions. This is usually deﬁ  ned as any adverse 
event occurring during or within 1 to 2 hours post infusion. 
The most common symptoms and signs are fever, chills, 
nausea and rarely chest pain, labile blood pressure, pruritus 
and urticaria. Slowing the rate of infusion and premedication 
with an antihistamine may ameliorate the reaction. Those 
who develop anti-inﬂ  iximab antibodies seem particularly 
prone to reactions. Anaphylactic reactions have been reported 
(less than 1% of patients) in post-marketing surveillance. 
A guideline for the prevention and treatment of infusion 
reactions has recently been published (Lecluse et al 2008).
Hepatotoxicity
Asymptomatic elevation in transaminases (alanine amino-
transferase more than aspartate aminotransferase) has been 
documented in clinical trials both when inﬂ  iximab was used 
as a montherapy and in combination with other immunosup-
pressives. There is a tendency for the abnormalities to resolve 
or decrease with continued inﬂ  iximab with consideration 
given to altering concomitant medication. Severe liver injury 
including reversible cholestasis and liver failure, occurring 
between a few weeks after commencement of inﬂ  iximab to 
1 year post initiation, has been reported rarely. Reactivation 
of hepatitis B has occurred in chronic carriers.
Immunogenicity
Anti-inﬂ  iximab antibodies have been detected in 27% to 47% 
of inﬂ  iximab-treated rheumatoid arthritis patients and appear 
to correlate with decreased serum inﬂ  iximab levels and the 
need for escalating dosing regimens and possibly the loss of 
efﬁ  cacy seen in some patients with time (Haraoui et al 2006; 
Wolbink et al 2006). The concomitant use of methotrexate 
may prevent development of these antibodies (Bendtzen et al 
2006). This has not been investigated in phase 3 studies in 
psoriasis.
Malignancy
An increased risk of lymphoma has been noted in the clinical 
portion of trials of TNF blockers. It is not clear whether this 
risk relates to disease severity, previous treatments or a combi-
nation of factors. An increased risk of lymphoma is recognized 
in severe rheumatoid arthritis, psoriasis and systemic inﬂ  am-
mation. Confounding factors include previous phototherapy, 
sun exposure, smoking and systemic therapies. A meta-
analysis of 9 trials of inﬂ  iximab or adalimumab in rheumatoid 
arthritis suggested a 3-fold increased risk of malignancy in 
the anti TNF alpha-treated group (OR 3.3, 95% CI 1.2–9.1) 
(Bongartz et al 2006). Cutaneous malignancies, speciﬁ  cally Therapeutics and Clinical Risk Management 2008:4(6) 1172
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non-melanoma skin cancers accounted for 9/35 cancers. 
This apparent excess risk occurred mainly after high 
dose inﬂ  iximab ( 6 mg/kg) which exceeds the dose usually 
used in rheumatoid arthritis and in psoriasis. The malignancy 
rate in the controlled arms was unexpectedly low, raising the 
possibility that the apparent increased risk in the TNF blocker 
group is simply a reﬂ  ection of the low rate of malignancy in 
the control arm. The validity and conclusions from the study 
have been debated and questioned by clinicians. (Dixon et al 
2006). It is likely that clariﬁ  cation of the relative importance of 
risk factors will come from the long term treatment registers 
of patients receiving biological therapies.
An increased incidence of hepatosplenic T cell lymphoma 
has been reported with infliximab. One hundred cases 
worldwide have been reported with 8 associated with 
inﬂ  iximab used to treat pediatric inﬂ  ammatory bowel disease. 
All patients were receiving concurrent immunosuppressant 
and/or prednisolone (Mackey et al 2007).
Cardiac failure
Initially TNF inhibitors were trialled as a treatment for 
congestive heart failure (CHF). Lack of efﬁ  cacy halted 
investigation. New or young age at onset CHF and CHF in 
the absence of identiﬁ  able risk factors have all been reported 
in post-marketing reports of TNF inhibitors. Withdrawal 
of inﬂ  iximab usually leads to improvement/resolution of 
symptoms (Kwon et al 2003).
Demyelination
TNF has been implicated in the pathogenesis of multiple 
sclerosis (Arnason et al 1999). A causal relationship 
between inﬂ  iximab and demyelinating disease remains to 
be established but optic neuritis, transverse myelitis and 
multiple sclerosis (MS) have all been reported in patients 
being treated with TNF blockers (Mohan et al 2001). 
A prior history of MS or optic neuritis or these conditions 
in a ﬁ  rst degree relative necessitates caution in the use of 
inﬂ  iximab.
Auto antibodies/lupus like 
syndromes
The development of antinuclear antibodies and anti-DNA 
antibodies appears to be relatively common with inﬂ  iximab 
treatment (Poulalhon et al 2007). The clinical signiﬁ  cance of 
these remains to be deﬁ  ned. The development of antibodies 
does not preclude further infusions unless signs or symptoms 
of lupus develop. Resolution of lupus-like syndromes usually 
occurs on cessation of inﬂ  iximab.
Other adverse events
Post-marketing surveillance across specialities has revealed 
occasional reports of neutropenia, interstitial pneumonitis, 
thrombocytopenic purpura (idiopathic and thrombotic), 
vasculitis, erythema multiforme, toxic epidermal necrolysis, 
transverse myelitis, Guillain Barré syndrome and neuropa-
thies. Weight gain has been reported in patients with inﬂ  am-
matory bowel disease and spondyloarthropathies treated with 
TNF antagonists. Similar ﬁ  ndings in the psoriasis population 
(Gisondi et al 2007) are important as chronic plaque psoriasis 
has been shown to be associated with obesity and may even 
be a risk factor for the disease (Mallbris et al 2005; Naldi 
et al 2005).
Comparative efﬁ  cacy
To date, there are no published trials directly comparing 
the efﬁ  cacy of inﬂ  iximab with systemic therapies such 
as methotrexate, ciclosporin or retinoids, or with other 
biological therapies. An indirect comparison of inﬂ  iximab 
and other biological therapies was undertaken by NICE 
using methodology from the health technology assessment 
of etanercept and inﬂ  iximab. This showed a greater efﬁ  cacy 
in terms of PASI 75 with inﬂ  iximab compared to efalizumab 
or etanercept (Scottish Medicines Consortium 2007). Further 
support was lent by the British Association of Dermatolo-
gists guideline for the management of psoriasis which, at the 
time of writing, noted that data from short-term individual 
studies suggested that inﬂ  iximab may be the most efﬁ  cacious 
biological therapy for psoriasis (Smith et al 2005).
Combination therapy
The synergistic effect of combining methotrexate and 
inﬂ  iximab has been described in the rheumatology litera-
ture (Maini et al 1998). This may, in part, be the result of 
methotrexate-induced alteration in inﬂ  iximab excretion. 
In Crohn’s disease and rheumatoid arthritis, a lack of 
sustained response to inﬂ  iximab, despite dose escalation, 
may prompt the addition of methotrexate which has been 
shown to decrease the development of human antichemeric 
antibodies (Maini et al 1998; Farrell et al 2001).
The place of inﬂ  iximab
in clinical practice
The National Institute for Health and Clinical Excellence 
(NICE) and the Scottish Medicines Consortium (SMC) have 
issued guidance about the place of inﬂ  iximab in the treatment 
of adults with psoriasis and psoriatic arthritis. NICE is an Therapeutics and Clinical Risk Management 2008:4(6) 1173
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independent organization responsible for providing national 
guidance on treatments and care for people using the NHS 
in England and Wales. Similarly, the SMC provides advice 
on newly licensed medicines in Scotland.
NICE recommends inﬂ  iximab for patients with severe 
disease (PASI 20 or more and a DLQI of greater than 18) 
who have failed, are intolerant of or have contraindication 
to treatment with standard systemic therapies such as ciclo-
sporin, methotrexate or PUVA. Continuation of inﬂ  iximab 
beyond 10 weeks requires a PASI 75 response or a PASI 50 
in addition to a 5-point reduction in the DLQI.
For adults with psoriatic arthritis, inﬂ  iximab may be 
prescribed if there are 3 or more tender and 3 or more swollen 
joints in addition to treatment failure with at least 2 standard 
disease-modifying anti-rheumatic drugs administered indi-
vidually or in combination. Infliximab is recommended 
only after intolerance of, or contraindications to, etanercept. 
An inability to self administer etanercept is considered an 
acceptable reason to progress to therapy with inﬂ  iximab. For 
treatment to continue beyond 12 weeks an improvement in 
at least two of the four PsARC criteria (one of which has to 
be joint tenderness or swelling, with no worsening in any of 
the four criteria) is required.
The financial savings and costs associated with 
implementing the NICE guidelines on inﬂ  iximab for psoriasis 
can be estimated, in the UK, using a template available at 
www.nice.org.uk/TA134.
In our own practice, inﬂ  iximab is chosen for individuals 
with severe disease, frequently involving skin and joints, 
in whom rapid control is desirable. Delivery of the drug 
is by intravenous infusion in a hospital setting permitting 
us to monitor concordance with treatment, efﬁ  cacy and to 
readily assess side effects. Intravenous delivery is particu-
larly suitable for those with severe joint disease who may 
not be dextrous enough to self administer treatment.
Conclusion
Studies have demonstrated that inﬂ  iximab is an effective 
treatment for chronic plaque psoriasis with 90% of patients 
becoming clear or having minimal disease activity after 
5 mg/kg infused at weeks 0, 2 and 6. Thereafter, maintenance 
infusions at approximately 8-weekly intervals may encour-
age prolonged efﬁ  cacy. There are fewer data about use in 
erythrodermic psoriasis and in generalized pustular psoriasis 
but the drug appears to be effective in this setting. In some 
patients with very severe or unstable disease concomitant 
systemic therapy may give added beneﬁ  t. Treatment with 
inﬂ  iximab is continued beyond 10 weeks only when an 
objective response (measured using PASI and DLQI scores) 
can be demonstrated.
Psoriasis tends to be a chronic disease and those who 
are most severely affected frequently require medical 
intervention over many years. Treatment regimens need to 
be tailored to individual patients taking in to consideration 
co-morbidities, the pattern, extent and psychological impact 
of psoriasis. A multi-disciplinary approach is often helpful. 
The establishment of registries such as the BAD biologics 
register (BADBIR) will undoubtedly yield useful and 
important data on long term safety and efﬁ  cacy of biological 
therapies such as inﬂ  iximab.
Disclosures
JAL has undertaken trials for Schering Plough, Merck Serono 
and Abbott. ADB has consulted to, undertaken trials for and 
lectured on behalf of Schering Plough, Wyeth, Merck Serono, 
Abbott and Janssen Cilag.
References
Antoni C, Kavanaugh A, Kirkham B, et al. 2005a. Sustained beneﬁ  ts of 
inﬂ  iximab therapy for dermatologic and articular manifestations of 
psoriatic arthritis: results from the Inﬂ  iximab Multinational Psoriatic 
Arthritis Controlled Trial. Arthritis Rheum, 52:1227–36.
Antoni C, Krueger GG, de Vlam K, et al. 2005b. Inﬂ  iximab improves signs 
and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann 
Rheum Dis, 64:1150–75.
Arnason BGW 1999. The lenercept Multiple Sclerosis Study Group and the 
University of British Columbia MS/MRI Analysis Group. TNF neutrali-
sation in MS: results of a randomised. placebo controlled multicentre 
study. Neurology, 53:457–65.
Bendtzen K, Geborek P, Svenson M et al. 2006. Individualized monitoring 
of drug bioavailability and immogenicity in rheumatoid arthritis patients 
treated with tumour necrosis factor alpha inhibitor inﬂ  iximab. Arthritis 
Rhem, 54:3782–89.
Benoit S, Toksoy A, Brocker EB et al. 2004. Treatment of recalcitrant 
pustular psoriasis with inﬂ  iximab: effective reduction of chemokine 
expression. Br J Dermatol, 150:1009–12.
Bianchi L, Bergamin A, de Felice C, et al. 2005. Remission and time of 
resolution of nail psoriasis during infliximab therapy. J Am Acad 
Dermatol, 52:736–7.
Bongartz T, Sutton AJ, Sweeting MJ, et al. 2006. Anti-TNF antibody 
therapy in rheumatoid arthritis and the risk of serious infections and 
malignancies: systematic review and meta-analysis of rare harmful 
effects in randomized controlled trials. JAMA, 295:2275–85.
Bundu-Kamara S. 2002. Therapeutic Management of psoriasis Hospital 
Pharmacist 9:191–99.
Burd RM. 2006. Psoriasis: a general overview. Br J Hosp Med, 67:259–62.
Camp RDR, El-Rachkidy RG, Young HS, et al. 2006. Immunological 
evidence for increasing reactivity to secreted Streptococcus 
pyogenes proteins in chronic plaque psoriasis: FC-13. Br J Dermatol, 
154(Suppl 1):5.
Capon F, Di Meglio P, Szaub J, et al. 2007. Sequence variants in the genes 
for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer 
protection against psoriasis. Hum Genet, 122(2):201–6.
Carlin CS, Feldman SR, Krueger JG, et al. 2004. A 50% reduction in the 
Psoriasis Area and Severity Index (PASI 50) is a clinically signiﬁ  cant 
endpoint in the assessment of psoriasis. J Am Acad Dermatol 
50:859–66.Therapeutics and Clinical Risk Management 2008:4(6) 1174
Leman and Burden
Cather J, Menter A . 2005. Combining traditional agents and biologics for 
treatment of psoriasis. Semin Cut Med Surg, 24:37–45.
Centocor Inc. 2006. Remicade (inﬂ  iximab) package insert: Chicago, Il, 
USA available at www.gene.com/gene/products/information/pdf/
raptivaprescribing.pdf.
Clements SE, Abdul-Ghaffar S, Grifﬁ  ths CE. 2006. Biological therapy for 
psoriasis. Br J Hosp Med(Lond), 67:184–7.
Collamer A, Guerrero KT, Henning JS, et al. 2008. Psoriatic skin lesions 
induced by tumour necrosis factor antagonist therapy: a literature review 
and potential mechanisms of action .Arthritis Care and Research, 
57:996–1001.
Cookson WO. Ubhi B. Lawrence R et al. 2001. Genetic linkage of childhood 
atopic dermatitis to psoriasis susceptibility loci. Nature Genetics, 
27(4):372–3.
Dixon W, Silman A. 2006. Is there an association between anti-TNF 
antibody therapy in rheumatoid arthritis and risk of malignancy and 
serious infection? Commentary on the meta analysis by Bongartz et al. 
Arthritis Res Ther, 8:11.
Dixon WG, Symmons DP, Lunt M, et al. 2007.Rates of serious infection, 
including site-specific and bacterial intracellular infection, in 
rheumatoid arthritis patients receiving anti-tumor necrosis factor 
therapy: results from the British Society for Rheumatology Biologics 
Register (BSRBR). Arthritis Rheum, 56:2896–904.
Elder JT. 2006.PSORS 1: linking genetics and immunology. J Invest 
Dermatol, 126:1205–6.
Espinoza LR, Cuellar ML, Silveira JH. 1992. Psoriatic arthritis. Curr Opin 
Rheumatol, 4:470–8.
Farrel RJ, Alsahli M, Falchuk KR, et al. 2001. Human ant-chimaeric 
antibody levels correlate with a lack of response and infusion reactions 
following inﬂ  iximab therapy. Gastroenterology, 120(Suppl 1):A69 
abstract 364.
Feldman SR, Krueger GG. 2005. Psoriasis assessment tools in clinical 
practice. Ann Rheum Dis, 64(Suppl ii):65–8.
Feldman SR, Gordon KB, Bala M, et al. 2005. Infliximab results in 
signiﬁ  cant improvement in the quality of life of patients with severe 
psoriasis: a double – blind placebo-controlled trial. J Am Acad Dermatol, 
152:954–60.
Finlay AY. 2005. Current severe psoriasis and the rule of tens. Br J Dermatol, 
152:861–7.
Gelﬂ  and JM, Weinstein R, Porter SB, et al. 2005. Prevalence and treatment 
of psoriasis in the United Kingdom: a population – base study. Arch 
Dermatol, 141:1537–41.
Gelfand JM, Neimann AL, Shin DB, et al. 2006. Risk of myocardial 
infarction in patients with psoriasis. JAMA, 296:1735–41.
Gilhar A, David M, Ullman T, et al. 1997. T-lymphocyte dependence of 
psoriatic pathology in human psoriatic skin grafted to SCID mice. 
J Invest Dermatol, 109:283–8.
Gisondi P, Cotena C, tessari G, et al. 2007. Anti-tumour necrosis factor alpha 
therapy increases bodt weight in patients with chronic plaque psoriasis: 
a retrospective cohort study. J Eur Acad Dermatol, 22:341–4.
Gladman D, Antoni C, Mease P, et al. 2005. Psoriatic arthritis: epidemiology, 
clinical features, course and outcome. Ann Rheum Dis, 64(SuppI 1):14–7.
Gottlieb AB, Evans R, Li S, et al. 2004. Inﬂ  iximab induction therapy for 
patients with severe plaque-type psoriasis: a randomised double-blind, 
placebo-controlled trial. J Am Acad Dermatol, 51:534–42.
Gudmundsdottir AS, Sigmundsdotir H, Sigurgeirsson B, et al. 1999. Is an 
epitope on keratin 17 a major target for autoreactive T lymphocytes in 
psoriasis? Clin Exp Dermatol. 117:580–6.
Haraoui B, Cameron L, Ouellet M, et al. 2006. Anti-inﬂ  iximab antibodies in 
patients with rheumatoid arthritis who require higher doses of inﬂ  iximab 
to achieve or maintain a clinical response. J Rheumatol, 33:31–6.
Hochberg MC, Lebwohl MG, Plevy, et al. 2005. The beneﬁ  t/risk proﬁ  le of 
TNF – blocking agents: ﬁ  ndings of a concensus panel. Semin Arthritis 
Rheum, 34:819–36.
Hyrich KL, Symmons DPM, Watson KD, et al. 2006. Pregnancy outcome in 
women who were exposed to anti-tumour necrosis factor agents: results 
from a national population register. Arthritis Rheum, 54:2701–8.
Kavanaugh A, Krueger GG, Beutler A, et al. 2007. Inﬂ  iximab maintains a 
higher degree of clinical response through 1 year of treatment: results 
from the IMPACT 2 trial. Ann Rheum Dis, 66:498–505.
Krueger JG. 2002. The immunological basis for the treatment of psoriasis 
with new biological agents. J Am Acad Dermatol, 46:1–23.
Kwon HJ, Cote TR, Cuffe MS, et al. 2003. Case reports of heart failure 
after therapy with tumour necrosis factor antagonist. Ann Intern Med, 
138:807–11.
Lebowohl M. 2003. Psoriasis. Lancet, 361:1197–204.
Lebowohl M, Callen JP. 2006. Obesity, smoking and psoriasis. JAMA, 
295:208–10.
Lecluse LLA, Piskin G, Mekkes JR, et al. 2008. Review and expert opinion 
on the prevention and treatment of inﬂ  iximab-related infusion reactions. 
Br J Dermatol, 159:527–36.
Lewis V, Finlay AY. 2004. 10 years experience of the Dermatology Life 
Quality index (DLQI) J Invest Dermatol Symp Proc, 9:169–8.
Lewis TG, Tuchinda C , Lim HW, et al. 2006. Life threatening pustular and 
eythrodermic psoriasis responding to inﬂ  iximab. J Drugs Dermatol, 
5:546–8.
Lomholt G. 1963. Psoriasis: prevalence, spontaneous course, and genetics. 
GEC, GAD, Copenhagen.
Mackkey AC, Green L, Liang LC, et al. 2007. Hepatosplenic T cell 
lymphoma associated with inﬂ  iximab use in young patients treated 
for inflammatory bowel disease. J Pediatr Gastroenterol Nutr, 
44:265–7.
Maini RN, Breedveld FC, Kalden JR, et al. 1998. Therapeutic efﬁ  cacy of 
multiple intravenous infusions of anti-tumour necrosis factor alpha 
monoclonal antibody combined with low dose weekly methotrexate 
in rheumatoid arthritis. Arthritis Rheum, 41:1552–63.
Mallbris L, Arke O, Granath F, et al. 2004. Increased risk for cardiovascular 
mortality in psoriasis inpatients but not outpatients. Eur J Epidemiol, 
19:225–30.
Mallbris L, Larsson P, Bergqvist S, et al. 2005. Psoriasis phenotype at 
disease onset: clinical characterisation of 400 adult cases. J Invest 
Dermatol, 124:499–504.
Martínez-Morán C, Sanz-Muñoz C, Morales-Callaghan AM, et al. 2007. 
Pustular psoriasis induced by inﬂ  iximab. J Eur Acad Dermatol Venereol, 
21:1424–6.
Mease P, Goffe B. 2005. Diagnosis and treatment of psoriatic arthritis. J Am 
Acad Dermatol, 52:1–19.
Mease PJ, Antoni CE, Gladman DD et al. 2005. Psoriatic arthritis assessment 
tools in clinical trials. Ann Rheum Dis, 64:ii49-ii54.
Mease PJ, Menter A. 2006. Quality of life issues in psoriasis and psoriatic 
arthritis:Outcome measure and therapies from a dermatological perspec-
tive. J Am Acad Dermatol, 50:859–66.
Menter M, Alan MD, Cush JM, et al. 2004. Successful treatment of pediatric 
psoriasis with inﬂ  iximab. Paed Dermatol, 21:87–8.
Menter A, Feldman SR, Weinstein GD, et al. 2007. A randomised 
comparison of continuous vs intermittent inﬂ  iximab maintenance 
regimens over 1 year in the treatment of moderate-severe plaque 
psoriasis. J Am Acad Dermatol, 56:31.e1–15.
Mohan N, Edwards ET, Cupps TR, et al. 2001. Demyelination occurring 
during anti-tumour necrosis factor alpha for inﬂ  ammatory arthritidies. 
Arthritis Rheum, 44:2862–9.
Moll JM, Wright V. 1973. Psoriatic arthritis. Semin Arthritis Rheum 
3:55–78.
Mossner R, Thaci D, Mohr J, et al. 2008. Manifestation of palmoplantar 
pustulosis during or after inﬂ  iximab therapy for plaque type psoriasis: 
report on ﬁ  ve cases. Arch Dermatol Res, 30:101–5.
Naldi L, Chatenoud L, Linder D, et al. 2005. Cigarette smoking, body mass 
index, and stressful life events as risk factors for psoriasis: results from 
an Italian case control study. J Inves Dermatol, 125:61–7.
NICE. 2006. Inﬂ  iximab for the treatment of adults with psoriasis- Final 
Scope. NICE single technology appraisal [online]. URL: www.nice.
org.uk/TA134.
Nickoloff BJ. 1999. The cytokine network in psoriasis. Arch Dermatol, 
127:871–84.Therapeutics and Clinical Risk Management 2008:4(6) 1175
Inﬂ  iximab for severe psoriasis
Pereira TM, Vieira AP, Fernandes JC, et al. 2006. Anti-TNF alpha in 
childhood pustular psoriasis. Dermatology, 213:350–2.
Poikolainen K, Karvonen J, Pukkala E. 1999. Excess mortality related to 
alcohol and smoking among hospital treated patients with psoriasis. 
Arch Dermatol, 135:1490–3.
Poulalhon N, Begon E Lebbe C, et al. 2007. A follow up study in 28 patients 
treated with inﬂ  iximab for severe recalcitrant psoriasis: evidence for efﬁ  cacy 
and high incidence of biological immunity. Br J Dermatol, 156;329–36.
Rapp SR, Feldman SR, Exum ML, et al. 1999. Psoriasis causes as much 
disability as other major medical diseases. J Am Acad Dermatol, 
41:401–7.
Raval A, Akhavan-Toyserkani G, Brinker A et al. 2007. Brief communica-
tion: characteristics of spontaneous cases of tuberculosis associated 
with Inﬂ  iximab. Ann Int Med, 147;699–702.
Reich K, Nestle FO, Papp K, et al. 2005. Infliximab induction and 
maintenance for moderate-to-severe psoriasis: a phase III, multi centre, 
double-blind trial. Lancet, 366:1367–74.
Rich P, Grifﬁ  ths CE, Reich K, et al. 2008. Baseline nail disease in patients 
with moderate to severe psoriasis and response to treatment with 
inﬂ  iximab during 1 year. J Am Acad Dermatol, 58:224–31.
Rigopoulos D, Gregoriou S, Stratigos A, et al. 2008. Evaluation of the 
efﬁ  cacy and safety of inﬂ  iximab on psoriatic nails: an unblinded, 
nonrandomized, open-label study. Br J Dermatol, 159:453–6.
Rott S, Kuster RM, Mrowietz U. 2007. Successful treatment of severe psoriatic 
arthritis with inﬂ  iximab in an 11 year old child suffering from linear 
psoriasis along the lines of Blaschko. Br J Dermatol, 157:191–2.
Routhouska SB, Sheth PB, Korman NJ. 2008. Long-term management of 
generalized ustular psoriasis with inﬂ  iximab: case series. J Cut Med 
Surg, 12:184–8.
Scheinfeld N. 2004. A comprehensive review and evaluation of the side 
effects of tumour necrosis factor alpha blockers, etanercept, inﬂ  iximab 
and adalimumab. Dermatol Treat, 15:280–94.
Scher RK. 1985. Psoriasis of the nail. Dermatol Clin, 3:387–94.
Schmick K, Grabbe J. 2004. Recalcitrant, generalized pustular pso-
riasis: rapid and lasting therapeutic response to anti tumour necrosis 
factor-alpha antibody (inﬂ  iximab). Br J Dermatol, 150:367.
Scottish Medicines Consortium guidance on inﬂ  iximab 100 mg powder for 
intravenous infusion (Remicade) No (318/06) 2007.
Setty AR, Curhan G, Choi HK. 2007. Obesity, waist circumference, 
weight change and the risk of psoriasis in women. Arch Intern Med, 
167:1670–5.
Smith CH, Anstey AV, Barker, et al. 2005. British Association of 
Dermatologists guideline for the use of biological interventions in 
psoriasis. Br J Dermatol, 153:486–97.
Smith CH, Barker JN. 2006. Psoriasis and its management. BMJ, 333:380–4.
Takahashi MD, Castro LG, Romiti R. 2007. Infliximab, as sole or 
combined therapy, induces rapid clearing of erythrodermic psoriasis. 
Br J Dermatol, 157:828–31.
Telfer NR, Chalmers RJ, Whale K, et al. 1992. The role of streptococcal 
infection in the initiation of guttate psoriasis. Arch Dermatol, 
128:39–42.
Trent JT, Kerdel FA. 2004. Successful treatment of Von Zumbush pustular 
psoriasis with inﬂ  iximab. J Cut Med Surg, 8:224–8.
Uyanik BS, Ari Z Omur E, et al. Serum lipids and apolipoproteins in patients 
with psoriasis. 2002. Clin Chem Lab Med, 40:65–8.
Valdimarsson H, Sigmundsdottir H, Jonsdottir I. 1997. Is psoriasis 
induced by streptococcal superantigens and maintained by 
M-protein-speciﬁ  c T cells that cross react with keratin? Clin Exp 
Dermatol, 107(Supp 1):21–4.
Van de Kerkhof P. 2003. Biologic agents offer hope for psoriasis. Business 
brieﬁ  ng: European Pharmacotherapy. p124–8.
Vieira Serrao V, Martins A, Lopes MJ .2008. Inﬂ  iximab in recalcitrant 
generalised pustular arthropathic psoriasis. Eur J Dermatol, 18:71–2.
Weisenseel P, Prinz JC. 2006. Sequential use of inﬂ  iximab and etanercept 
in generalized pustular psoriasis Cutis, 78:197–9.
Wolbink GJ, Vis M, Lems W, et al. 2006. Development of anti-inﬂ  iximab 
antibodies and relationship to clinical response in patients with 
rheumatoid arthritis. Arthritis Rheum, 54:711–5.
Wollina U, Hansel G, Koch A, et al. 2008. Tumour necrosis factor alpha 
inhibitor induced psoriasis or psoriasiform exanthemata: ﬁ  rst 120 cases 
from the literature including a series of six new patients. Am J Clin 
Dermatol, 9:1–14.